Glaxo set to ask investors to keep the faith

Years of underwhelming pipeline performance and a weak pandemic showing have left Glaxosmithkline one of big pharma’s laggards. Executives now face a massive test at an investor event on Wednesday, at which they will try to reset expectations and convince shareholders about new growth targets.